Fig. 3.

Differences in clinical performance (sensitivity and specificity) for the detection of at-risk MASH between ≤45 and ≥65 years age groups by cut-off.

Matched cohort, n = 708. At-risk MASH was defined as MASH with MAS ≥4 and F ≥2. APRI, aspartate aminotransferase-to-platelet ratio index; ALT, alanine aminotransferase; APRI, aspartate aminotransferase-to-platelet ratio index; ELF™, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; MAS, MASLD activity score; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction-associated liver disease; NAFLD, non-alcoholic fatty liver disease; NFS, NAFLD fibrosis score.